Enveda discovers medicines by studying the chemistry of nature and translating natural compounds into potential therapeutic candidates.
Enveda has raised $311.0M in total funding. The most recent round was Series E. The last funding was announced in September 2026.
Enveda's investors include Lightspeed Venture Partners, Catalio Capital Management, Lux Capital, FPV Ventures, T. Rowe Price.
Enveda is headquartered in Boulder, United States.
Enveda discovers medicines by studying the chemistry of nature and translating natural compounds into potential therapeutic candidates.
Enveda is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Enveda — Funding & Investors." VCBacked, September 23, 2026, https://www.vcbacked.co/company/enveda. Accessed October 1, 2026.
VCBacked. (2026). Enveda — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/enveda
{{cite web |title=Enveda — Funding & Investors |url=https://www.vcbacked.co/company/enveda |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated